Tagraxofusp is a CD123 interaction indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. It is available as injection for intravenous use. MedsAcross supplies Tagraxofusp for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. ELZONRIS is a CD123-directed cytotoxin indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older
Source: US FDA prescribing information
Tagraxofusp-erzs is a CD123-directed cytotoxin composed of recombinant human interleukin-3 (IL-3) and truncated diphtheria toxin (DT) fusion protein that inhibits protein synthesis and causes cell death in CD123-expressing cells.
Source: US FDA prescribing information
Premedicate with an H1-histamine antagonist, acetaminophen, corticosteroid and H2-histamine antagonist prior to each ELZONRIS infusion. Administer ELZONRIS intravenously at 12 mcg/kg over 15 minutes once daily on days 1 to 5 of a 21-day cycle. Administer the first cycle of ELZONRIS in the inpatient setting. Subsequent cycles may be administered in the inpatient or appropriate outpatient setting. Additional important preparation and administration information is in full prescribing information. See full prescribing information for instructions on preparation and administration.
Source: US FDA prescribing information
None. None
Source: US FDA prescribing information
Boxed warning (capillary leak syndrome): Capillary Leak Syndrome (CLS) which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended. Capillary Leak Syndrome (CLS), which may be life-threatening or fatal if not properly managed, can occur in patients receiving ELZONRIS. Hypersensitivity: Monitor patients for signs/symptoms and treat appropriately. Hepatotoxicity: Monitor ALT and AST. Interrupt ELZONRIS if the transaminases rise to greater than 5 times the upper limit of normal.
Source: US FDA prescribing information
The following serious adverse drug reactions are described elsewhere in the labeling: Capillary Leak Syndrome Hypersensitivity Reactions Hepatotoxicity Most common adverse reactions (incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue, pyrexia, peripheral edema, and weight increase. Most common laboratory abnormalities (incidence ≥ 50%) are decreases in albumin, platelets, hemoglobin, calcium, and sodium, and increases in glucose, ALT and AST.
Source: US FDA prescribing information
Store in freezer between -25°C and -15°C (-13°F and 5°F). Thaw vials at room temperature between 15°C and 25°C (59°F and 77°F) prior to preparation.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Tagraxofusp, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Elzonris 1000 mcg/1 mL injectionIntravenous Cold chain | Stemline Therapeutics | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Tagraxofusp and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Tagraxofusp, including Elzonris.
Yes. The US FDA first approved Tagraxofusp on 21 December 2018, according to Drugs@FDA.
Yes. Tagraxofusp has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Tagraxofusp must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Tagraxofusp is classified under ATC code L01XX67 (Tagraxofusp).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.